Document Detail


Novel angiotensin II inhibitors in cardiovascular medicine.
MedLine Citation:
PMID:  11772299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Blockade of the renin-angiotensin-aldosterone cascade is now recognised as a very effective approach to treat hypertensive, heart failure and high cardiovascular risk patients and to retard the development of renal failure. The purpose of this review is to discuss the state of development of currently available drugs blocking the renin-angiotensin system, such as angiotensin converting enzyme (ACE) inhibitors, renin inhibitors and angiotensin II receptor antagonists, with a special emphasis on the results of the most recent trials conducted with AT(2) receptor antagonists in heart failure and Type 2 diabetes. In addition, the future perspectives of drugs with dual mechanisms of action, such as NEP/ACE inhibitors, also named vasopeptidase inhibitors, are presented.
Authors:
M Burnier
Related Documents :
16542179 - Immunohistochemical localization of distinct angiotensin ii at1 receptor isoforms in th...
18434439 - Angiotensin and nmda receptors in the median preoptic nucleus mediate hemodynamic respo...
9826909 - Angiotensin at1 receptor subtypes in the rabbit pulmonary artery. a ligand binding study.
12669109 - Travoprost: a potent ocular hypotensive agent.
21050909 - Assessment of inverse agonism for the angiotensin ii type 1 receptor.
15448979 - A pharmacological differentiation between postjunctional (at1a) and prejunctional (at1b...
2241909 - Modulation of mannose receptor activity by proteolysis.
9264549 - Ingestion of candida albicans down-regulates mannose receptor expression on rat macroph...
21198789 - A study of apai and taqi genotypes of the vitamin d receptor in egyptian patients with ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  10     ISSN:  1354-3784     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2002-01-04     Completed Date:  2002-03-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1957-64     Citation Subset:  IM    
Affiliation:
Division of Hypertension and Vascular Medicine,Av. P. Decker, 1011 Lausanne, Switzerland. Michel.Burnier@chuv.hospvd.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II / antagonists & inhibitors*,  metabolism
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use
Animals
Cardiovascular Agents / adverse effects,  therapeutic use*
Cardiovascular Diseases / drug therapy*
Clinical Trials as Topic
Humans
Protease Inhibitors / adverse effects,  therapeutic use
Receptors, Angiotensin / antagonists & inhibitors
Renin / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiovascular Agents; 0/Protease Inhibitors; 0/Receptors, Angiotensin; 11128-99-7/Angiotensin II; EC 3.4.23.15/Renin
Comments/Corrections
Erratum In:
Expert Opin Investig Drugs. 2002 Jan;11(1):151

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inhaled nitric oxide in cardiology.
Next Document:  Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction.